The global trivalent flu vaccine market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). These shots, also known as Fluad (trivalent) is another alternative for flu vaccines that are granted for people ages 65 and older. It includes an ingredient called an adjuvant, which also creates a stronger immune system response. The market is anticipated to see remarkable growth owing to the critical development undertaken for these vaccines. The constantly rising R&D expenditure in the medical sector, coupled with the government support to address the seasonal flu cases are some factors contributing to accelerate the market growth. An increase in awareness among the population is another factor that is pushing the growth of this market. The geriatric population is more prone to catch seasonal flu which globally raises the burden on healthcare authorities. Thus, to address this issue which rises with the growing geriatric population, the market is anticipated to gain substantial traction. However, fake immunization by unauthorized individuals is expected to hamper the growth of this market.

The recent outbreak of COVID-19 has exponentially upsurged the trivalent flu vaccine market, especially in emerging economies. Adding to this, the trivalent flu vaccine benefits have also contributed substantially to this market growth. The population explosion, investment and funding by different companies have combinedly upsurged the growth of the trivalent flu vaccine market. A trivalent flu vaccine is a synthetic vaccine consisting of three inactivated influenza viruses, two different influenza type A strains, and one influenza type B strain. Generally, the trivalent influenza vaccine is devised every year, based on influenza strains prevalent in the flu season. Thus, the rising cases of flu all over the globe are anticipated to spur market growth.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Sanofi-Aventis Group, AstraZeneca plc, and Abbott Laboratories, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Trivalent Flu Vaccine Market by Segment

By Type 

• Intramuscular Injection

• Nasal Spray

• Intradermal Shot

By Application 

• Hospital

• Clinic

• Public Health Agency

Global Trivalent Flu Vaccine Market by Region